Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (30125)	1/11/2000 3:21:00 PM
From: Alper H.YUKSEL	Read Replies (1) \| Respond to of 32384

A rather anemic coverage of LGND's presentation by CBS Marketwatch : Ligand in position Ligand Pharmaceuticals Chief Executive Officer David Robinson said his company is positioned to be one of the major biotech companies of the new millenium. He said a recent series of "value creating activities," including three new oncology approvals, will drive growth at Ligand (LGND: news, msgs). The company hopes the drugs Ontak and Targretin will help it reach its goal of profitability this year, Robinson said. Other objectives include pursuing new uses for its existing drugs and strengthening the company's balance sheet.